Kenvue Inc. (NYSE:KVUE) Shares Sold by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. decreased its stake in Kenvue Inc. (NYSE:KVUE) by 18.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 397,589 shares of the company’s stock after selling 90,292 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Kenvue were worth $9,196,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Riverview Trust Co purchased a new position in Kenvue in the third quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue during the 3rd quarter valued at about $35,000. Deseret Mutual Benefit Administrators increased its stake in shares of Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Studio Investment Management LLC increased its stake in shares of Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares in the last quarter. Finally, AlphaMark Advisors LLC acquired a new position in Kenvue in the 3rd quarter worth about $77,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 0.1 %

KVUE stock opened at $24.11 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average of $22.84 and a two-hundred day moving average of $20.87. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.31. The company has a market cap of $46.23 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period in the prior year, the business posted $0.31 earnings per share. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. As a group, analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.40%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of recent analyst reports. Bank of America boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. boosted their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group assumed coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.